SYDNEY, AUSTRALIA — Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novell LAG-3 immunotherapies for cancer and autoimmune disease, today announces positive results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial evaluating eftilagimod alfa (efti) in combination with MSD’s (Merck & Co., Inc., Rahway, NJ,...
Latest News
For the estimated 100,000 people living with sickle cell disease (SCD) in the United States, pain is a common occurrence. [1,2] In addition to the acute pain resulting from vaso-occlusive crises (VOCs), many of individuals with SCD suffer from chronic pain and associated comorbidities such as depression and anxiety. [2]...
VANCOUVER, BC — According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the rise in the EU. Sadly, this is a trend that’s happening in North America too, especially among young people. Perhaps the most concerning are the incidences of pancreatic cancer, which while...
SYDNEY, Australia — Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is pleased to announce exciting new data from its Phase 1b clinical trial evaluating azer-cel (azercabtagene zapreleucel) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). In February 2025, Imugene announced that a total of four out of seven patients had achieved a Complete...
Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed Gynecologic Oncology, suggest very meaningful survival effect of IMNN-001 in women HRP and HRD positive, including those with BRAC1 and...
LAWRENCEVILLE, N.J. — IMUNON, Inc. (Nasdaq: IMNN) (“IMUNON” or “the Company”), a clinical-stage biotechnology company developing its novel DNA-mediated immunotherapies, today is providing a progress update on its pivotal Phase 3 OVATION 3 trial of IMNN-001 in patients with newly diagnosed advanced ovarian cancer. Since initiating the trial, the Company...
LAWRENCEVILLE, N.J. — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that it has been invited to present a trials-in-progress abstract on the ongoing Phase 3 OVATION 3 clinical trial of IMNN-001, its investigational therapy for the treatment of women with...
LAWRENCEVILLE, N.J. — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Independent Data Monitoring Committee (IDMC) overseeing its ongoing Phase 2 minimal residual disease (MRD) translational study of IMNN-001 has reviewed all safety data to date and recommended that the study continue without...
LAWRENCEVILLE, N.J. — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that a trials-in-progress abstract on the ongoing Phase 3 OVATION 3 clinical trial of IMNN-001, its investigational therapy for the treatment of women with newly diagnosed advanced ovarian cancer, was...
PHILADELPHIA, PA — Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced that an abstract reporting results from the Company’s randomized, multicenter, double-blind, placebo-controlled Phase 2b trial of IGV-001 in 99 patients with newly diagnosed glioblastoma (ndGBM) has been accepted for poster and rapid oral presentation...